VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that BetterLife is working with its collaborators on a key research publication on BETR-001…


Previous articleMindMed to Participate in H.C. Wainwright Global Investment ConferenceUSA – EnglishUSA – EnglishUSA – English
Next articleMindset Pharma Files National Patents Protecting Family 1 Application in 16 Different Countries